Zobrazeno 1 - 10
of 83
pro vyhledávání: '"Giulia Marzocchi"'
Autor:
Carolina Terragna, Andrea Poletti, Vincenza Solli, Marina Martello, Elena Zamagni, Lucia Pantani, Enrica Borsi, Ilaria Vigliotta, Gaia Mazzocchetti, Silvia Armuzzi, Barbara Taurisano, Nicoletta Testoni, Giulia Marzocchi, Ajsi Kanapari, Ignazia Pistis, Paola Tacchetti, Katia Mancuso, Serena Rocchi, Ilaria Rizzello, Michele Cavo
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-18 (2024)
Abstract The complexity of Multiple Myeloma (MM) is driven by several genomic aberrations, interacting with disease-related and/or -unrelated factors and conditioning patients’ clinical outcome. Patient’s prognosis is hardly predictable, as commo
Externí odkaz:
https://doaj.org/article/b0670f38bd1042f68b22b11a9e85ac10
Autor:
Ilaria Vigliotta, Vincenza Solli, Silvia Armuzzi, Ajsi Kanapari, Andrea Poletti, Barbara Taurisano, Ignazia Pistis, Enrica Borsi, Gaia Mazzocchetti, Marina Martello, Ilaria Rizzello, Lucia Pantani, Giulia Marzocchi, Nicoletta Testoni, Elena Zamagni, Mario Terracciano, Valentina Del Monaco, Marianna Garonzi, Nicolò Manaresi, Michele Cavo, Carolina Terragna
Publikováno v:
HemaSphere, Vol 7, p e182325c (2023)
Externí odkaz:
https://doaj.org/article/c282c23606b6444ca6b39d7948fc0300
Autor:
Francesca Palandri, Fausto Castagnetti, Nicoletta Testoni, Simona Luatti, Giulia Marzocchi, Simona Bassi, Massimo Breccia, Giuliana Alimena, Ester Pungolino, Giovanna Rege-Cambrin, Riccardo Varaldo, Maurizio Miglino, Giorgina Specchia, Eliana Zuffa, Felicetto Ferrara, Monica Bocchia, Giuseppe Saglio, Fabrizio Pane, Daniele Alberti, Giovanni Martinelli, Michele Baccarani, Gianantonio Rosti
Publikováno v:
Haematologica, Vol 93, Iss 12 (2008)
Background Imatinib mesylate is the first line treatment for chronic myeloid leukemia. In patients with advanced phase of the disease, the advent of imatinib significantly increased survival. However, few long-term data, based on large, prospective a
Externí odkaz:
https://doaj.org/article/3f6cd0d8cc154c3abf09a722043029a1
Autor:
Simona Soverini, Sabrina Colarossi, Alessandra Gnani, Fausto Castagnetti, Gianantonio Rosti, Costanza Bosi, Stefania Paolini, Michela Rondoni, Pier Paolo Piccaluga, Francesca Palandri, Panagiota Giannoulia, Giulia Marzocchi, Simona Luatti, Nicoletta Testoni, Ilaria Iacobucci, Daniela Cilloni, Giuseppe Saglio, Michele Baccarani, Giovanni Martinelli
Publikováno v:
Haematologica, Vol 92, Iss 3 (2007)
The emergence of resistance to the Bcr-Abl inhibitor imatinib mesylate in patients with Philadelphia chromosome-positive (Ph+) leukemia has prompted the development of second-generation compounds active against several imatinib-insensitive mutant for
Externí odkaz:
https://doaj.org/article/8907d98d9e554c64b972ccf45d8f6f92
Autor:
Michele Cavo, Stefano Fanti, Ilaria Rizzello, Enrica Borsi, Giulia Marzocchi, Marina Martello, Carolina Terragna, Serena Rocchi, Annamaria Brioli, Ilaria Rambaldi, Beatrice Zannetti, Lucia Pantani, Annalisa Pezzi, Paola Tacchetti, Katia Mancuso, Cristina Nanni, Elena Zamagni
Supplementary Tables 1 and 2. Supplementary Table 1 describes Summary of FDG PET/CT positivity criteria Supplementary Table 2 contains Univariate analysis of baseline and post-treatment variables adversely affecting progression-free survival and over
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::104736fd0a745eca8a51127b331dd7e0
https://doi.org/10.1158/1078-0432.22458894.v1
https://doi.org/10.1158/1078-0432.22458894.v1
Autor:
Michele Cavo, Stefano Fanti, Ilaria Rizzello, Enrica Borsi, Giulia Marzocchi, Marina Martello, Carolina Terragna, Serena Rocchi, Annamaria Brioli, Ilaria Rambaldi, Beatrice Zannetti, Lucia Pantani, Annalisa Pezzi, Paola Tacchetti, Katia Mancuso, Cristina Nanni, Elena Zamagni
Purpose: To evaluate the role of 18F-FDG PET/CT in 282 symptomatic multiple myeloma patients treated up-front between 2002 and 2012.Experimental Design: All patients were studied by PET/CT at baseline, during posttreatment follow-up, and at the time
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1db73d9d38647b5fb3d5521217a284b8
https://doi.org/10.1158/1078-0432.c.6524070
https://doi.org/10.1158/1078-0432.c.6524070
Autor:
Carmen Baldazzi, Simona Luatti, Giulia Marzocchi, Alessandra Grassi, Michele Cavo, Nicoletta Testoni
Publikováno v:
Cancer Genetics. :35-39
The translocation t(5;12)(q31;p13)/ETV6::ACSL6 is a rare cytogenetic abnormality, although it is reported in various myeloid malignancies. To date, only 16 cases of t(5;12) and ETV6::ACSL6 rearrangement, confirmed by either molecular or Fluorescence
Autor:
Carolina Terragna, Andrea Poletti, Vincenza Solli, Marina Martello, Enrica Borsi, Elena Zamagni, Lucia Pantani, Gaia Mazzocchetti, Ilaria Vigliotta, Silvia Armuzzi, Barbara Taurisano, Paola tacchetti, Katia Mancuso, Serena Rocchi, Ignazia Pistis, Giulia Marzocchi, Nicoletta Testoni, Michele Cavo
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:S77-S78
Autor:
Paola Tacchetti, Lucia Pantani, Francesca Patriarca, Maria Teresa Petrucci, Elena Zamagni, Luca Dozza, Monica Galli, Francesco Di Raimondo, Claudia Crippa, Mario Boccadoro, Simona Barbato, Patrizia Tosi, Franco Narni, Vittorio Montefusco, Nicoletta Testoni, Antonio Spadano, Carolina Terragna, Norbert Pescosta, Giulia Marzocchi, Claudia Cellini, Piero Galieni, Sonia Ronconi, Marco Gobbi, Lucio Catalano, Antonio Lazzaro, Giovanni De Sabbata, Clotilde Cangialosi, Fabrizio Ciambelli, Pellegrino Musto, Francesca Elice, Michele Cavo, Renato Fanin, Roberto Foa', Alessandro Rambaldi, Giuseppe Rossi, Pietro Leoni, Paolo Corradini, Giuseppe Torelli, Giuseppe Fioritoni, Sergio Cortelazzo, Giorgio Lambertenghi Deliliers, Giorgio La Nasa, Alfonso Zaccaria, Paolo De Fabritiis, Nicola Cascavilla, Alberto Bosi, Gianpietro Semenzato, Luigi Gugliotta, Filippo Gherlinzoni, Emanuele Angelucci, Massimo Fabrizio Martelli, Maria Concetta Petti, Giuseppe Leone, Angelo Michele Carella, Fabio Ciceri, Armando Santoro, Felicetto Ferrara, Francesco Nobile, Alfonso Maria D'Arco, Alessandro Levis, Luciano Guardigni, Andrea Gallamini, Pier Paolo Fattori, Sergio Morandi, Dino Amadori, Bruno Rotoli, Salvatore Mirto, Giorgio Paladini, Ruggero Mozzana, Graziella Pinotti, Francesco Rodeghiero, Nicola Cantore, Vincenzo Pavone, Enrico Maria Pogliani, Anna Marina Liberati, Ignazio Majolino, Sergio Amadori, Francesco Lauria, Massimo Aglietta, Giovanni Quarta, Sergio Storti, Fortunato Morabito, Silvana Franca Capalbo, Alessandro Massimo Gianni, Vincenzo Mettivier, Vittorio Rizzoli, Carlo Bernasconi, Giuseppe Visani, Michele Pizzuti, Giacinto La Verde, Giuseppe Avvisati, Maurizio Longinotti, Eugenio Gallo, Franco Dammacco, Domenico Russo, Andrea Bacigalupo, Caterina Musolino
Publikováno v:
The Lancet Haematology. 7:e861-e873
Background: The phase 3 GIMEMA-MMY-3006 trial, which compared bortezomib, thalidomide, and dexamethasone (VTD) combination therapy with thalidomide and dexamethasone (TD) as induction therapy before and consolidation therapy after double autologous h
Autor:
Giulia Marzocchi, Luca Dozza, Angela Bonalumi, Elisabetta Antonioli, Lucia Pantani, Chiara Di Giovanni Bezzi, Marina Martello, Anna Furlan, Michela Staderini, Elena Zamagni, Mario Petrini, Paola Tacchetti, Michele Cavo, Katia Mancuso, Marco Scalese, Ilaria Rizzello, Gregorio Barilà, Gabriele Buda, Michele Cea, Serena Rocchi, Micol Quaresima
Carfilzomib–lenalidomide–dexamethasone (KRd) has been approved for the treatment of relapsed/refractory multiple myeloma (RRMM). We conducted a retrospective analysis of 197 RRMM patients (pts) between January 2016 and March 2018 in six Italian h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97fea9e4d4d4ad198217daaf8831ae18
http://hdl.handle.net/11585/804597
http://hdl.handle.net/11585/804597